FOXP3 and rheumatoid arthritis: Low-dose IL-2 therapy has shown to be effective in inducing the expansion of CD4+CD25+FoxP3+ T cells in clinical trials in autoimmune diseases including T1D [131], SLE [132] and RA [133] (Table 2).